Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)
John M Zajecka,1,2 Arielle D Stanford,3 Asli Memisoglu,4 William F Martin,5 Sanjeev Pathak3 1Department of Psychiatry, Rush University Medical Center, Chicago, IL, USA; 2Psychiatric Medicine Associates, LLC, Skokie, IL, USA; 3Department of Clinical Research, Alkermes, Inc., Waltham, MA, USA; 4Depar...
Enregistré dans:
Auteurs principaux: | Zajecka JM, Stanford AD, Memisoglu A, Martin WF, Pathak S |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/fa8ef40e4dfd43178a91a5049d49e805 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Donepezil reverses buprenorphine-induced central respiratory depression in anesthetized rabbits
par: SAKURABA,SHIGEKI, et autres
Publié: (2009) -
Effects of Buprenorphine on the Memory and Learning Deficit Induced by Methamphetamine Administration in Male Rats
par: Farshid Etaee, et autres
Publié: (2021) -
Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records
par: Ker S, et autres
Publié: (2021) -
Association between Participation in Counseling and Retention in a Buprenorphine-Assisted Treatment Program for People Experiencing Homelessness with Opioid Use Disorder
par: Amanda R. W. Berry, et autres
Publié: (2021) -
Comparison of spinal analgesia with Lidocaine plus Buprenorphine and Lidocaine alone
par: M Rabiei, et autres
Publié: (2004)